![](https://www.longwoodfund.com/wp-content/uploads/2024/03/Engrail-Logo-2500.2.jpg)
Engrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience. Engrail is committed to rapidly advancing our innovative, precision-targeted therapeutics with a purpose to deliver transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.